Skip to main content
. 2005 May;26(5):1101–1106.

TABLE 3:

Regional rCBF before and after treatment

rCBF (ml/min/100g) Before Treatment 6 Months After Treatment P Value*
Symptomatic patients (n = 10)
    Resting 23.3 ± 5.1 26.8 ± 7.3 .1849
    Acetazolamide 27.1 ± 5.1 38.0 ± 12.4 .0166
    ΔF 3.9 ± 2.7 11.2 ± 7.0 .0367
Asymptomatic patients (n = 4)
    Resting 28.8 ± 8.2 30.1 ± 6.4 >.05
    Acetazolamide 38.4 ± 7.6 47.4 ± 8.6 .0679
    ΔF 9.7 ± 2.6 17.2 ± 6.9 .0679
*

Wilcoxon signed rank test.

Acetazolamide rCBF − resting rCBF.